Abstract
Most cell types can release vesicles. Cell-derived vesicles are increasingly recognized as an evolutionary wide-spread mechanism of intercellular communication. The paracrine and long range activity of vesicles and their regulated cargo-composition endows these vesicles with regulatory properties beyond that of the parental cell. The release and biogenesis of cell-derived vesicles is a dynamic and tightly controlled process. In the past years it has become clear that these vesicles exert a plethora of biological effects. This has sparked the intense interest in these vesicles in relation to (patho)physiological processes. This review focuses on the role of cell-derived vesicles in inflammation, with emphasis on the immune modulating capacity of immune cell-derived vesicles. The biological activity of different leukocyte-derived vesicles is compared, and potential explanations for the strong biological effects exhibited by vesicles are provided. The role of cell-derived vesicles in inflammatory processes is discussed by speculating how these vesicles can contribute to allergic inflammation.
Keywords: Exosome, microvesicle, microparticle, membrane vesicle, ectosome, allergy, immune regulation, immune cells
Current Pharmaceutical Design
Title:Immune Cell-derived Vesicles: Modulators and Mediators of Inflammation
Volume: 18 Issue: 16
Author(s): Esther N.M. Nolte-‘t Hoen and Marca H.M. Wauben
Affiliation:
Keywords: Exosome, microvesicle, microparticle, membrane vesicle, ectosome, allergy, immune regulation, immune cells
Abstract: Most cell types can release vesicles. Cell-derived vesicles are increasingly recognized as an evolutionary wide-spread mechanism of intercellular communication. The paracrine and long range activity of vesicles and their regulated cargo-composition endows these vesicles with regulatory properties beyond that of the parental cell. The release and biogenesis of cell-derived vesicles is a dynamic and tightly controlled process. In the past years it has become clear that these vesicles exert a plethora of biological effects. This has sparked the intense interest in these vesicles in relation to (patho)physiological processes. This review focuses on the role of cell-derived vesicles in inflammation, with emphasis on the immune modulating capacity of immune cell-derived vesicles. The biological activity of different leukocyte-derived vesicles is compared, and potential explanations for the strong biological effects exhibited by vesicles are provided. The role of cell-derived vesicles in inflammatory processes is discussed by speculating how these vesicles can contribute to allergic inflammation.
Export Options
About this article
Cite this article as:
N.M. Nolte-‘t Hoen Esther and H.M. Wauben Marca, Immune Cell-derived Vesicles: Modulators and Mediators of Inflammation, Current Pharmaceutical Design 2012; 18 (16) . https://dx.doi.org/10.2174/138161212800166013
DOI https://dx.doi.org/10.2174/138161212800166013 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Modulation of the Type I Interferon Response Defines the Sensitivity of Human Melanoma Cells to Oncolytic Measles Virus
Current Gene Therapy 3-Bromopyruvic Acid, A Hexokinase II Inhibitor, is an Effective Antitumor Agent on the Hepatoma Cells : in vitro and in vivo Findings
Anti-Cancer Agents in Medicinal Chemistry Mesenchymal Stem Cells Promote Caspase Expression in Molt-4 Leukemia Cells <i>Via</i> GSK-3α/Β and ERK1/2 Signaling Pathways as a Therapeutic Strategy
Current Gene Therapy Lactate Transporters and pH Regulation: Potential Therapeutic Targets in Glioblastomas
Current Cancer Drug Targets Targeting CREB for Cancer Therapy: Friend or Foe
Current Cancer Drug Targets Epigenetics in Vascular Disease – Therapeutic Potential of New Agents
Current Vascular Pharmacology Biological Agents Involved in Malignant Mesothelioma: Relevance as Biomarkers or Therapeutic Targets
Current Cancer Drug Targets Engineering Nanomedicines to Overcome Multidrug Resistance in Cancer Therapy
Current Medicinal Chemistry The c-Met Inhibitors: A New Class of Drugs in the Battle Against Advanced Nonsmall- Cell Lung Cancer
Current Pharmaceutical Design Editorial [Hot Topic: The Therapeutic Potential of Ribonucleases (Guest Editor: Urich Arnold) ]
Current Pharmaceutical Biotechnology Berberine as a Promising Safe Anti-Cancer Agent- Is there a Role for Mitochondria?
Current Drug Targets Anticancer Properties of the IL-12 Family - Focus on Colorectal Cancer
Current Medicinal Chemistry Discovery and Application of the Yoshida Effect: Nano-Sized Acicular Materials Enable Penetration of Bacterial Cells by Sliding Friction Force
Recent Patents on Biotechnology Toward The Rational Design of Cell Fate Modifiers Notch Signaling as a Target for Novel Biopharmaceuticals
Current Pharmaceutical Biotechnology Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Aflibercept: A Novel VEGF Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Tumors
Mini-Reviews in Medicinal Chemistry Chromatin Remodeling Agents for Cancer Therapy
Reviews on Recent Clinical Trials KIAA0101 in Malignant Pleural Mesothelioma: A Potential Diagnostic and Prognostic Marker
Combinatorial Chemistry & High Throughput Screening Efficacy and Safety of the Combination of Docetaxel (Taxotere®) with Targeted Therapies in the Treatment of Solid Malignancies
Current Drug Targets Therapeutic Strategies for Targeting BRAF in Human Cancer
Reviews on Recent Clinical Trials